Kidney damage: The Tipline for 21 February 2019
The snow has started to melt and federal offices in Washington, DC, are back open. Today, we dig into the Federal Trade Commission’s approval of a merger between two kidney treatment companies, as well as dissents from both Democratic commissioners who think the deal could damage competition in the market for dialysis machines. As it's nearly the end of the week, we’re also indulging in some antitrust news about wine and medical weed.
To read more
Subscribe to Global Competition Review
Subscribe and start reading now
Global Competition Review (GCR) is a leading global provider of competition law, regulation and enforcement information, combining data, deep market insight and a user-centric platform to provide our clients with powerful legal solutions.
Already have access? Login below
Copyright © Law Business ResearchCompany Number: 03281866 VAT: GB 160 7529 10